Kelactin 50Mcg/Ml 7Ml

Target species Dog and cat. 4.2 Indications for use, specifying the target species The veterinary medicinal product is indicated for the following uses: - Treatment of false pregnancy in bitches - Suppression of lactation in bitches and queens 4.3 Contra-indications - Do not use in pregnant animals since the product may cause abortion. - Do not use with dopamine antagonist. - Do not use in case of hypersensitivity to the active substance or to any of the excipients. Cabergoline may induce transient hypotension in treated animals. Do not use in animals concurrently being treated with hypotensive drugs. Do not use directly after surgery whilst the animal is still under the influence of the anaesthetic agents. 4.4 Special warnings for each target species Additional supportive treatments should involve restriction of water and carbohydrate intake and increase exercise. 4.5 Special precautions for use i) Special precautions for use in animals Not applicable. (ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals Wash hand after use. Avoid contact with skin and eyes. Wash of any splashes immediately. Women of childbearing potential and breast-feeding woman should not handle the product or should wear disposable gloves when administering the product. People with known hypersensitivity to cabergoline or any of the other ingredients in the product should avoid contact with the veterinary medicinal product. Do not leave unattended filled syringes in presence of children. In the event of accidental ingestion, particularly by a child, seek medical attention immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Possible adverse effects are: - sleepiness - anorexia - vomiting These adverse effects are usually of a moderate and transient nature. Vomiting usually only occurs after the first administration. In this case treatment should not be stopped, since the vomiting will not reoccur after the following administrations. In very rare cases allergic reactions may occur, such as oedema, urticaria, dermatitis and pruritus. In very rare cases a transient hypotension may occur. In very rare cases neurological symptoms may occur, such as sleepiness, muscle tremor, ataxia, hyperactivity and convulsions. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use during pregnancy, lactation or lay - Cabergoline has the capacity to cause abortion in the later stages of pregnancy and should not be used in pregnant animals. Differential diagnosis between pregnancy and false pregnancy should be made correctly. - The product is indicated for the suppression of lactation: inhibition of prolactin secretion by cabergoline results in a rapid cessation of lactation and a reduction in the size of the mammary glands. The product should not be used in lactating animals unless suppression of lactation is required. 4.8 Interaction with other medicinal products and other forms of interaction Since cabergoline exerts its therapeutic effect by direct stimulation of dopamine receptors, the product should not be administered concurrently with drugs which have dopamine antagonist activity (such as phenothiazines, butyrophenones, metoclopramide), as these might reduce its prolactin inhibiting effects. Since cabergoline may induce transient hypotension, the product should not be used in animals concurrently treated with hypotensive drugs.